StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Lenvima (lenvatinib by Quarter

Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Lenvima (lenvatinib: $283M in Q2 2026, up 6.8% from a year earlier. That is the highest of the 37 quarters on record here.

Latest, Q2 2026
283
Period ended Jun 30, 2026
Change on a year earlier
+6.8%
265 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue – Lenvima (2) | 283 | 265 | 7 | 194 | 183 | 6 | 90 | 83 | 8”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026283+6.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026256-0.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025272+6.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025258+2.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025265+6.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025258+1.2%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024255+12.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024251-3.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 2024249+2.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 2024255+9.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 2023226+4.6%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 2023260+28.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 2023242+4.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 2023232+2.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 2022216+4.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 2022202+7.4%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up lenvima (lenvatinib

Cite this data

StockData. (2026). Merck Lenvima (lenvatinib ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lenvima

See every metric in the Merck KPI table. Data updated Oct 26, 2026.